Ariana® Pharma teams together with SIB Swiss Institute of Bioinformatics to discover novel biomarkers for gastric cancer

Ariana Pharma, developer of innovative clinical data analysis and diagnostic solutions for the healthcare sector, and SIB Swiss Institute of Bioinformatics, a world-class provider of bioinformatics resources and expertise, today announced their collaboration focusing on the discovery of novel biomarkers for gastric cancer.

Read more ...

How chameleons change colour and keep cool

Research led by SIB group leader Michel Milinkovitch (Laboratory of Artificial and Natural Evolution, University of Geneva), which was published last week in Nature Communications, created a bit of a global buzz. Aware of the strong physical component present in biological processes, Michel Milinkovitch uses techniques both from the fields of biology and of physics to understand them.

Read more ...

Study Examines Association of Genetic Variants with Cognitive Impairment

Individually rare but collectively common intermediate-size copy number variations may be negatively associated with educational attainment, according to a study in the May 26 issue of JAMA. Copy number variations (CNVs) are regions of the genome that differ in the number of segments of DNA.

Read more ...

New possibilities for the treatment of breast cancer arise with the help of mathematics

Researchers of three of Switzerland’s leading scientific institutions have brought to light a means of reprogramming a flawed immune response into an efficient anti-tumoral one by the results of a translational trial relating to breast cancer. Thanks to the innovative combination of mathematical modelization and experimentation, only 20 tests were necessary, whereas traditional experimentation would have required 596 tests to obtain the same results.

Read more ...

ELIXIR accelerates with major Horizon 2020 funding

ELIXIR has been awarded €19 million from the EU to accelerate the implementation of Europe’s life-science data infrastructure over the next four years. From September 2015, ‘ELIXIR-EXCELERATE’ will facilitate the integration of Europe’s bioinformatics resources, supporting all sectors of life-science R&D. It will deliver excellence to ELIXIR’s users by fast-tracking the development and deployment of essential data services.

Read more ...

SIB Swiss Institute of Bioinformatics contributing to largest ever genome-wide study strengthening genetic link to obesity

Findings help explain why some people are more likely than others to gain weight and develop obesity-related conditions Key findings The largest genetic association study ever has tripled the number of known genetic locations that play a role in obesity. While diet and exercise are important, the study sharpens the role genetics play in people’s tendency to gain weight and where the fat is stored.

Read more ...

GTEx - How DNA differences influence gene activity and disease

Researchers co-led by Emmanouil Dermitzakis, geneticist at the University of Geneva (UNIGE) Faculty of Medicine and at the SIB Swiss Institute of Bioinformatics, have created a new and much-anticipated data resource to help them find out how differences in an individual’s genetic make-up can affect gene activity and contribute to disease.

Read more ...

SIB Swiss Institute of Bioinformatics designated an FAO Reference Centre

The Food and Agriculture Organization of the United Nations (FAO) has appointed SIB Swiss Institute of Bioinformatics as the FAO Reference Centre for bioinformatics. SIB’s expertise together with its state-of-the-art scientific services led to the choice of the Institute.

Read more ...
Page 2 of 2